Parkinsonism
| Parkinsonism | |
|---|---|
| Classification and external resources | |
| Specialty | neurology |
| ICD-10 | G21, G22 |
| ICD-9-CM | 332 |
| DiseasesDB | 24212 |
| MedlinePlus | 000759 |
| MeSH | D020734 |
Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability.[1][2] Parkinsonism is found in Parkinson's disease (after which it is named), however a wide range of other causes may lead to this set of symptoms, including some toxins, a few metabolic diseases, and a handful of neurological conditions other than Parkinson's disease.[3]
About 7% of people with parkinsonism have developed their symptoms following treatment with particular medications. Side effect of medications, mainly neuroleptic antipsychotics especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupenthixol and zuclopenthixol) and butyrophenones (such as haloperidol), piperazines (such as ziprasidone), and rarely, antidepressants. The incidence of drug-induced parkinsonism increases with age. Drug-induced parkinsonism tends to remain at its presenting level, not progress like Parkinson's disease.[4]
Differential diagnoses
Differentiating some kinds of atypical Parkinson: Northwest Parkinson Foundation
Before Parkinson's disease is diagnosed, the differential diagnoses include:
- AIDS can sometimes lead to the symptoms of secondary parkinsonism, due to commonly causing dopaminergic dysfunction. Indeed, parkinsonism can be a presenting feature of HIV infection.[5]
- Corticobasal degeneration[1]
- Creutzfeldt–Jakob disease[6]
- Dementia pugilistica or "boxer's dementia" is a condition that occurs in athletes due to chronic brain trauma.
- Diffuse Lewy body disease[1]
- Drug-induced parkinsonism ("pseudoparkinsonism") due to drugs such as antipsychotics, metoclopramide, MPTP[1][7]
- Encephalitis lethargica[1]
- Essential tremor, an illness which has some diagnostic overlap with Parkinson's disease[8]
- Orthostatic tremor
- MDMA addiction and frequent use has been linked to Parkonsonism. Several cases have been reported where individuals are diagnosed with the syndrome after taking MDMA.[9]
- Multiple system atrophy[10]
- Pantothenate kinase-associated neurodegeneration, also known as neurodegeneration with brain iron accumulation or Hallervorden-Spatz syndrome[11][12]
- Parkinson plus syndrome
- Progressive supranuclear palsy[1]
- Toxicity due to substances such as carbon monoxide,[13] carbon disulfide,[13] manganese,[13] paraquat,[14] mercury,[15] hexane, rotenone, Annonaceae, and toluene[16] (inhalant abuse: "huffing")[17]
- Vascular parkinsonism, associated with underlying cerebrovascular disease[18][19]
- Wilson's disease is a genetic disorder in which an abnormal accumulation of copper occurs. The excess copper can lead to the formation of a copper-dopamine complex, which leads to the oxidation of dopamine to aminochrome.[20] The most common manifestations include bradykinesia, cogwheel rigidity[21] and a lack of balance.[22]
- Paraneoplastic syndrome: neurological symptoms caused by antibodies associated with cancers
- Genetic
- Rapid onset dystonia parkinsonism
- Parkin mutation
- X-linked dystonia parkinsonism
- Autosomal recessive juvenile parkinsonism
References
- 1 2 3 4 5 6 Aminoff MJ, Greenberg DA, Simon RP (2005). Clinical Neurology (6th ed.). Lange: McGraw-Hill Medical. pp. 241–5. ISBN 0-07-142360-5.
- ↑ Bradley J. Robottom; William J. Weiner; Lisa M. Shulman. "42". International Neurology: A Clinical Approach. Blackwell Publishing Ltd. pp. 152–158. ISBN 978-1-405-15738-4.
- ↑ Christine CW, Aminoff MJ (2004). "Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance". Am. J. Med. 117 (6): 412–9. PMID 15380498. doi:10.1016/j.amjmed.2004.03.032.
- ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2013-06-26. Retrieved 2013-04-15.
- ↑ Tse W, Cersosimo MG, Gracies JM, et al. (2004). "Movement disorders and AIDS: a review". Parkinsonism Relat. Disord. 10 (6): 323–34. PMID 15261874. doi:10.1016/j.parkreldis.2004.03.001.
- ↑ Maltête D, Guyant-Maréchal L, Mihout B, Hannequin D (2006). "Movement disorders and Creutzfeldt–Jakob disease: a review". Parkinsonism Relat. Disord. 12 (2): 65–71. PMID 16364674. doi:10.1016/j.parkreldis.2005.10.004.
- ↑ Watanabe Y, Himeda T, Araki T (2005). "Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease" (PDF). Med. Sci. Monit. 11 (1): RA17–23. PMID 15614202.
- ↑ September 2, 2009 at 5:32 AM (2009-09-02). "LINGO1 variant responsible for essential tremors and Parkinson's disease". News-medical.net. Retrieved 2017-02-24.
- ↑ Fabrizi, Monaco, Dalla Libera (2004). "Parkinsonian syndrome following MDMA (Ecstasy) addiction". Movement Disorders. 19: S73–S74.
- ↑ Wenning GK, Geser F (2003). "Multiple system atrophy". Rev. Neurol. (Paris). 159 (5 Pt 2): 3S31–8. PMID 12773886.
- ↑ Uc EY, Rodnitzky RL (2003). "Childhood dystonia". Seminars in pediatric neurology. 10 (1): 52–61. PMID 12785748. doi:10.1016/S1071-9091(02)00010-4.
- ↑ Online Mendelian Inheritance in Man (OMIM) NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 1; NBIA1 -234200
- 1 2 3 DeLong MR, Juncos JL (2004). Parkinson's Disease and Other Movement Disorders. In: Harrison's Principles of Internal Medicine (16th ed.). McGraw-Hill Professional. p. 2414. ISBN 0-07-140235-7.
- ↑ Dinis-Oliveira RJ, Remião F, Carmo H, et al. (2006). "Paraquat exposure as an etiological factor of Parkinson's disease". Neurotoxicology. 27 (6): 1110–22. PMID 16815551. doi:10.1016/j.neuro.2006.05.012.
- ↑ Tremor/InvoluntaryMovements: Excerpt from Field Guide to Bedside Diagnosis Archived 2010-02-03 at the Wayback Machine.
- ↑ Weiss J. Chapter 151. Toluene and Xylene. In: Olson KR, ed. Poisoning & Drug Overdose. 6th ed. New York: McGraw-Hill; 2012. http://www.accessmedicine.com/content.aspx?aID=55982958. Accessed April 21, 2013.
- ↑ Uitti, Ryan J.; Snow, Barry J.; Shinotoh, Hitoshi; Vingerhoets, Francois J. G.; Hayward, Margo; Hashimoto, Stanley; Richmond, John; Markey, Sanford P.; Markey, Carol J.; Calne, Donald B. (1994). "Parkinsonism induced by solvent abuse". Annals of Neurology. 35 (5): 616. PMID 8179306. doi:10.1002/ana.410350516.
- ↑ Thanvi B, Lo N, Robinson T (2005). "Vascular Parkinsonism--an important cause of parkinsonism in older people" (PDF). Age and ageing. 34 (2): 114–9. PMID 15713855. doi:10.1093/ageing/afi025.
- ↑ "Parkinson's Insights: Vascular parkinsonism". Parkinsonsdiseasefoundation.blogspot.com. 2012-08-07. Retrieved 2017-02-24.
- ↑ Członkowska A, Tarnacka B, Möller JC, et al. (2007). "Unified Wilson's Disease Rating Scale — a proposal for the neurological scoring of Wilson's disease patients". Neurol. Neurochir. Pol. 41 (1): 1–12. PMID 17330175.
- ↑ Ropper AH, Samuels MA. Chapter 4. Abnormalities of Movement and Posture Caused by Disease of the Basal Ganglia. In: Ropper AH, Samuels MA, eds. Adams and Victor's Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009. http://www.accessmedicine.com/content.aspx?aID=3630437. Accessed April 21, 2013.
- ↑ Lorincz MT (January 2010). "Neurologic Wilson's disease". Ann. N. Y. Acad. Sci. 1184: 173–87. Bibcode:2010NYASA1184..173L. PMID 20146697. doi:10.1111/j.1749-6632.2009.05109.x.
External links
- GeneReviews/NIH/NCBI/UW entry on Perry syndrome
- GeneReviews/NCBI/NIH/UW entry on X-Linked Dystonia-Parkinsonism
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.